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IL-19 Is a Component of the Pathogenetic
IL-23/IL-17 Cascade in Psoriasis
Ellen Witte1,2, Georgios Kokolakis1,2, Katrin Witte1,2, Sandra Philipp1,2, Wolf-Dietrich Doecke3,
Nina Babel4,5, Bianca M. Wittig6, Katarzyna Warszawska1, Agata Kurek1,2, Magdalena Erdmann-Keding1,2,
Stefanie Kunz1,2, Khusru Asadullah3, Marshall E. Kadin7, Hans-Dieter Volk4,8, Wolfram Sterry9,
Kerstin Wolk1,2,10 and Robert Sabat1,2,10
Psoriasis is a common chronic inflammatory disease with characteristic skin alterations and functions as a model
of immune-mediated disorders. Cytokines have a key role in psoriasis pathogenesis. Here, we demonstrated that
out of 30 individually quantified cytokines, IL-19 showed the strongest differential expression between psoriatic
lesions and healthy skin. Cutaneous IL-19 overproduction was reflected by elevated IL-19 blood levels that
correlated with psoriasis severity. Accordingly, anti-psoriatic therapies substantially reduced both cutaneous and
systemic IL-19 levels. IL-19 production was induced in keratinocytes by IL-17A and was further amplified by tumor
necrosis factor-a and IL-22. Among skin cells, keratinocytes were found to be important targets of IL-19. IL-19
alone, however, regulated only a few keratinocyte functions. While increasing the production of S100A7/8/9 and,
to a moderate extent, also IL-1b, IL-20, chemokine C-X-C motif ligand 8, and matrix metalloproteinase 1, IL-19 had
no clear influence on the differentiation, proliferation, or migration of these cells. Importantly, IL-19 amplified
many IL-17A effects on keratinocytes, including the induction of b-defensins, IL-19, IL-23p19, and T helper type 17-
cell- and neutrophil-attracting chemokines. In summary, IL-19 as a component of the IL-23/IL-17 axis strengthens
the IL-17A action and might be a biomarker for the activity of this axis in chronic inflammatory disorders.
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INTRODUCTION
Psoriasis vulgaris (referred to as psoriasis) is a common,
chronic, inflammatory skin disease frequently accompanied
by arthritis as well as endocrine, cardiovascular, and meta-
bolic alterations (Schon and Boehncke, 2005; Griffiths and
Barker, 2007; Armstrong et al., 2013). Hyperproliferation and
disturbed differentiation of keratinocytes as well as growth and
dilatation of dermal papillae vessels underlie the psoriatic skin
alterations that appear as sharply demarcated, erythematous,
scaly plaques (Schon and Boehncke, 2005; Griffiths and
Barker, 2007). Despite the disturbed barrier function of these
lesions, they are highly protected against bacterial and viral
infections, which is due to the strong local upregulation of
anti-bacterial and anti-viral proteins (Ong et al., 2002; Wolk
et al., 2013).
Although the pathogenesis of psoriasis is not fully under-
stood, it is widely accepted that cytokines play a key role in
both emergence and maintenance of psoriatic lesions. Accord-
ingly, numerous immune mediators play been described as
being elevated in the diseased skin of these patients (Sabat
et al., 2007). Among them are members of the IL-10 cytokine
family—namely, IL-19, IL-20, IL-24, IL-22, IL-26, and IL-29
(Romer et al., 2003; Wolk et al., 2004; Kunz et al., 2006;
Wolk et al., 2013). The cellular sources of these family
members differ; in fact, IL-22, IL-26, and IL-29 are secreted
by T cells and innate lymphoid cells, whereas IL-24 is
preferentially produced by dendritic cells/macrophages and
keratinocytes (Romer et al., 2003; Donnelly et al., 2010;
Kumari et al., 2013; Wolk et al., 2013; Sabat et al., 2014).
IL-19 and IL-20 expression in psoriasis has been solely located
in keratinocytes as impressively demonstrated by the Kragballe
group (Romer et al., 2003). With the exception of IL-10, the
IL-10 family members do not act on immune cells but instead
target certain tissue cells (Sabat, 2010). Despite this, transgenic
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overexpression of IL-20, IL-22, and IL-24 in mice led to very
similar psoriatic-like skin alterations (Blumberg et al., 2001;
Wolk et al., 2009a; He and Liang, 2010). Moreover, inhibition
of these cytokines’ action reduced cutaneous pathological
alterations in murine dermatitis models (Ma et al., 2008;
Stenderup et al., 2009; Kumari et al., 2013). This appears
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to be caused by the direct effects of these mediators
on the keratinocytes, leading to their disturbed differentiation
and chemokine production as demonstrated by in vitro
studies (Wolk et al., 2006; Sa et al., 2007; Wolk et al.,
2009a; Kumari et al., 2013). Moreover, some IL-10
family members might have an essential role in the
elevated anti-microbial competence of psoriatic lesions:
IL-20, IL-22, and IL-24 strongly enhance the expression
of anti-bacterial proteins in keratinocytes (Wolk et al., 2004;
Sa et al., 2007; Kumari et al., 2013), whereas the elevated
anti-viral defense of psoriatic lesions seems to be dependent
on IL-29 (Wolk et al., 2013). In contrast to IL-20, IL-22, IL-24,
and IL-29, the roles of IL-19 and IL-26 were largely
unexplored so far.
In this study, we compared the expression of a broad range
of cytokines belonging to different cytokine families (including
the IL-1, IL-12/IL-23, IL-10, and IL-17 families) in psoriatic
lesions and came across the outstanding upregulation of IL-19
in this situation. This let us characterize the induction, target
cells, and effects of IL-19 with special focus on its interaction
with other cytokines and its classification into an important
pathogenetic cascade.
RESULTS
IL-19 dominates the local and systemic cytokine milieu in
psoriasis
In order to get a more thorough picture of the cutaneous
cytokine networks in psoriasis, we individually quantified
the messenger RNA (mRNA) expression of a broad range of
cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-9, IL-10, IL-12p35,
p40, IL-13, IL-17A, IL-17F, IL-18, IL-19, IL-20, IL-21, IL-22,
IL-23p19, IL-24, IL-25, IL-26, IL-27p28, IL-29, EBI3, IL-33,
IL-36g, tumor necrosis factor-a (TNF-a), macrophage colony-
stimulating factor (M-CSF), granulocyte-macrophage-CSF
(GM-CSF), OSM, IFN-b1, and IFN-g) in lesional skin from
psoriasis patients. The vast majority of analyzed mediators
were highly expressed in the lesions compared with skin from
healthy donors (Figure 1a and data not shown). Strikingly,
among all quantified cytokines, IL-19 was the most strongly
upregulated mediator with expressions several thousand times
higher in psoriatic skin compared with healthy skin
(Figure 1a). The lesional IL-19 mRNA upregulation was
accompanied by strong IL-19 protein production (Figure 1b).
Moreover, the cutaneous IL-19 dominance was reflected by
high systemic amounts of IL-19 protein (Figure 1c). In fact,
blood concentrations of this cytokine even exceeded those of
IL-20 and IL-22 by B10- and 5-fold, respectively, two
cytokines known for the strongly elevated systemic levels in
these patients. Importantly, IL-19 blood levels positively and
most significantly correlated with the disease severity repre-
sented by the psoriasis area and severity index value
(Figure 1d). Virtually no systemic levels of IL-19 were found
in healthy participants (Figure 1c and e). Analysis of further
immune-mediated conditions revealed that patients suffering
from asthma and Crohn’s disease, but not those after renal
transplantation, also showed increased IL-19 blood levels,
which, however, were far from reaching those of psoriasis
patients (Figure 1e).
Next, we investigated the influence of anti-psoriatic thera-
pies on the IL-19 levels in the skin and blood of psoriasis
patients. A pronounced drop of cutaneous IL-19 mRNA to
below 1% of the initial expression levels was induced by UV
radiation and TNF-a inhibition–based therapies (Figure 1f).
Strikingly, only a single application of ustekinumab induced a
marked decrease in blood IL-19 concentrations (Figure 1g).
Importantly, this decrease in blood IL-19 amounts seems to
precede that of the clinical improvement represented by
psoriasis area and severity index reduction. A similar behavior
of IL-19 levels was seen in patients after UV-based combina-
tion therapy (Figure 1g). These data demonstrate that blood
IL-19 level may show therapy response before the clinically
visible improvement in skin alterations.
IL-17A drives keratinocyte IL-19 production
The outstanding IL-19 production (Figure 1a and b) and its
location in the psoriatic lesion in the epidermis above the
dermal papillae only (Romer et al., 2003) suggested that
keratinocytes produce this cytokine in response to different
mediators of the psoriatic cytokine pool. On the basis of this
assumption, we first tested a range of cytokines overexpressed
in lesional psoriatic skin for their IL-19-inducing capacity
using primary human keratinocytes and epidermis models.
Whereas IL-6, IL-21, IL-22, IL-24, IFN-g, TNF-a, GM-CSF, or
IL-19 itself did not virtually provoke IL-19 production, we
found a marked IL-19 production driven by IL-17A (Figure 2a
and data not shown). This effect was exerted via transcrip-
tional regulation (Figure 2b). As IL-22 has been shown to
synergize with IL-17A in regulating keratinocyte functions
(Liang et al., 2006; Wolk et al., 2011), we investigated
whether the same is true regarding the keratinocyte IL-19
production. Indeed, although IL-22 itself did not clearly
induce IL-19 mRNA expression or protein secretion
(Figure 2a and c), its presence amplified the IL-17A-induced
levels (Figure 2c). As anti-TNF-a therapy reduced IL-19 levels
in psoriatic patients (Figure 1f) and an amplifying action of
TNF-a regarding some IL-22 effects has been observed (Wolk
Figure 1. IL-19 is highly present in the skin and blood of psoriasis patients. (a) Expression in skin biopsies from healthy individuals (n¼10) and psoriasis patients
(n¼ 16, except for IL-25 (n¼ 10)). (b) Concentration in the supernatant of skin biopsy cultures from psoriasis patients (n¼5) and healthy donors (n¼ 4) cultured for
20 hours. (c, d) Concentration in blood serum (IL-19) and plasma (IL-20, IL-22) from healthy donors (n¼ 13), psoriasis patients (n¼25); correlation with patients’
psoriasis area and severity index (PASI) values. (e) Concentration in serum from healthy donors (n¼ 26), asthma patients (n¼17), patients with Crohn’s disease
(n¼ 20), and transplanted patients (n¼ 20). (f) Expression in skin biopsies from psoriasis patients before/after anti-psoriatic therapies (n¼ 3). (g) PASI values and
IL-19 serum concentrations of psoriasis patients before (PASI: 10.1±0.6)/during ustekinumab therapy (n¼ 6) (PASI after 16wks: 4.4 ±1.0) and before (PASI:
14.1±1.4)/during UV-based combination therapy (n¼ 6; for details refer to the Materials and Methods section) (PASI after 2–5wks: 5.4±0.7). (a–c, e–g) Mean
data±s.e.m. HPRT, hypoxanthine-guanine phosphoribosyltransferase; M-CSF,macrophage colony-stimulating factor; mRNA, messenger RNA; OSM, oncostatin M;
TNF-a, tumor necrosis factor-a.
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et al., 2009a), we investigated the influence of TNF-a on the
IL-22 and IL-17A effects with respect to IL-19 production. As
demonstrated in Figure 2d, the combination of TNF-a with
only IL-22 had no IL-19-inducing effect. However, TNF-a
increased the IL-17A-induced IL-19 expression (Figure 2e).
Interestingly, the highest IL-19 production was observed when
keratinocytes were stimulated with the combination of IL-17A/
IL-22/TNF-a.
Keratinocytes are important IL-19 targets in the skin
Next, we questioned which cell types in the skin are targeted
by IL-19. IL-19 acts via a heterodimeric transmembrane
receptor composed of IL-20R1 and IL-20R2 (Dumoutier
et al., 2001). As a number of studies have excluded any
expression of IL-20R1 in immune cells (Sabat, 2010), we
focused on the analysis of skin-resident tissue cells for IL-19
receptor subunit expression. As demonstrated in Figure 3,
expression of IL-20R1 and IL-20R2 was virtually absent in
microvascular endothelial cells and melanocytes. Although
dermal fibroblasts clearly expressed IL-20R2, only marginal
levels of IL-20R1 mRNA were detectable in these cells. In
contrast, keratinocytes strongly expressed both IL-19 receptor
components (Figure 3), which highlights these cells as impor-
tant IL-19 target cells in the skin.
IL-19 regulates only a few functions of keratinocytes
Having identified keratinocytes as IL-19 target cells, we next
aimed to characterize the keratinocyte response to IL-19
stimulation. We investigated the influence of IL-19 on human
epidermal models and conventional keratinocyte cultures
regarding functions known to be altered in the psoriatic skin
as follows: (i) disturbed terminal differentiation, (ii) increased
proliferation, (iii) increased migratory capacity, (iv) increased
anti-bacterial competence, and (v) production of pro-inflam-
matory mediators. IL-19’s relative IL-22 was included in these
investigations as it is well known to regulate many of these
functions (Sabat et al., 2014). Surprisingly, IL-19 had no
relevant influence on the expression of molecules with a key
function in keratinocyte terminal differentiation, such as
keratin-10, calmodulin-like 5, desmocollin-1, and kallikrein-7
(Figure 4a). Consequently, there were no histologically visible
signs of a disturbed differentiation in IL-19-treated epidermis
models (Figure 4b). In contrast and in line with our previous
studies (Wolk et al., 2006, 2009a), IL-22 altered the expression
of molecules with key functions in keratinocyte terminal
differentiation and provoked acanthosis, hypogranularity,
and partly parakeratosis. IL-19 also had no influence on
keratinocyte proliferation, whereas interferon-b had a
reducing and IL-17A had a slightly inducing effect
(Figure 4c). Moreover, only minimal if any influence of IL-
19 could be detected on the keratinocyte migration in
wounded keratinocyte monolayers, whereas EGF was highly
potent in this regard as expected (Barrandon and Green,
1987); (Figure 4d). However, IL-19 increased the keratinocyte
production of the anti-bacterial proteins psoriasin (S100A7),
S100A8, and S100A9 (Figure 5a). Interestingly, this IL-19 effect
on the microbial defense was actually specific for these S100
proteins as no modulation was observed regarding
b-defensin (BD)2, BD3, lipocalin-2 , LL37/cathelicidin, and
RNAse7 (Figure 5a). IL-19 also slightly affected the expression
of a few molecules with inflammatory properties. In fact, a
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Figure 2. T helper type 17-cytokines drive keratinocyte IL-19 production.
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Mean data±s.e.m. contr., control; HPRT, hypoxanthine-guanine
phosphoribosyltransferase; mRNA, messenger RNA.
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stimulatory effect of IL-19 was observed on the expression of
IL-1b, IL-20, chemokine C-X-C motif ligand 8 (CXCL8),
and the extracellular matrix–degrading and migration-facilitat-
ing enzyme matrix metalloproteinase 1. No influence by
IL-19 was found regarding the expression of IL-6, IL-23p19,
IL-36g, GM-CSF, CXCL1, CXCL11, regenerating islet-derived
protein 3 alpha, or its own mRNA (Figure 5b and data not
shown).
IL-19 strengthens numerous IL-17A effects on keratinocytes
As demonstrated in Figure 1a, psoriatic lesions contain several
different mediators that might modulate the effects of indivi-
dual cytokines on their target cells. Hence, we screened for
the influence of selected cytokines (IL-6, IL-17A, IL-21, IL-22,
IL-23, TNF-a, GM-CSF, and IFN-g) on IL-19 action. Interest-
ingly, IL-17A clearly synergized with IL-19 (data not shown),
which prompted us to focus on the cooperative activity of
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both cytokines. Using epidermis models, we could demon-
strate that IL-19 increases the effect of IL-17A regarding
the expression of the anti-bacterial proteins BD2, BD3, and
S100A7 in a synergistic manner (Figure 6a and b). Similarly,
IL-19 synergized with IL-17A to upregulate the expression
of IL-1b, IL-20, IL-23p19, CXCL1, CXCL8, and CCL20
(Figure 6a and c). In contrast, IL-19 had no influence on the
IL-17A-induced IL-36g or lipocalin-2 expression, and IL-17A
did not promote IL-19-induced upregulation of matrix
metalloproteinase 1 mRNA (Figure 6a). Overall, most IL-17A
effects were amplified by IL-19. This amplification
might be based on the synergistic/additive activation of signal
transducer and activator of transcription 3 and c-Jun N-term-
inal kinase by both cytokines (Supplementary Figure S1
online).
The known absence of IL-20R1, the receptor used by IL-19,
on immune cells (Sabat, 2010) and the here described IL-19
effects (Figure 5b and Figure 6a–c) suggest a role of IL-19 in
local (cutaneous) but not systemic inflammation. Accordingly,
the inhibition of IL-20R1 profoundly reduced the cutaneous
production of pro-inflammatory cytokines and skin thickening
in the murine DNFB model of contact dermatitis (Figure 6d),
whereas it had no influence on the blood levels of
pro-inflammatory cytokines in lipopolysaccharide-induced
systemic inflammation in mice (Figure 6e).
DISCUSSION
The aim of our study was to illuminate the cytokine network in
psoriatic lesions. To address this aim, the cytokine pattern may
be assessed by different approaches including global screens
(microarray, mRNA sequencing) or specific individual quanti-
fication. Using highly quantitative real-time PCR analyzing a
broad range (n¼30) of cytokines, we detected an outstanding
expression of the IL-10 family member IL-19, a so far under-
appreciated mediator. Follow-up investigations identified IL-
19 as a component of the IL-23/IL-17 cascade, meaning that
IL-19 might especially contribute to the chronicity of the
pathologic interaction between immune cells and tissue cells.
This conclusion is drawn on the basis of the following
observations: First, IL-17A drives IL-19 production by kerati-
nocytes, which is further amplified by the psoriasis key
cytokines IL-22 and TNF-a. As an autocrine mediator, IL-19
acts on the keratinocytes. These cells seem to be the sole
target cells of this cytokine in the skin as deduced from our
analyses of skin tissue cells isolated from healthy donors. We
surprisingly found that IL-19 itself has no major impact on the
keratinocyte functions known to be characteristically altered
in psoriasis. A clear influence of IL-19 could be observed only
with respect to the production of anti-bacterial S100 proteins.
In addition, IL-19 slightly induced the production of some
inflammatory (IL-1b, CXCL8) and regeneration-promoting
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mediators (IL-20, matrix metalloproteinase 1). No influence
was found on keratinocyte differentiation, migration, or pro-
liferation, or on the production of further mediators. However,
IL-19 potentiated the action of IL-17A. This potentialization
might occur at the level of signal transduction. The IL-17
production is driven by IL-23, providing the reason for
referring to this relation as the IL-23/IL-17 cascade (Ouyang
et al., 2008). Many results point to the crucial role of this
cascade in psoriasis pathogenesis. First, different studies
demonstrated that IL-23/lL-17A contributes to experimental
cutaneous inflammation (Lowes et al., 2013). Furthermore,
several single nucleotide polymorphisms of IL-23-related
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genes have been described to be associated with the
susceptibility to psoriasis (Capon et al., 2007; Nair et al.,
2009). Moreover, anti-p40 and the recent IL-17 system–
targeting therapies are very effective in psoriasis (Leonardi
et al., 2008; Papp et al., 2008; Miossec and Kolls, 2012).
The consequences of the simultaneous presence of IL-19
and IL-17A in psoriasis lesions may have an impact on
different levels of the pathogenetic process. First, both cyto-
kines synergistically increase the anti-bacterial competence of
keratinocytes by upregulating the expression of b-defensins
and S100A proteins. Besides their function in preventing
infections, some of these proteins are reported to also have
chemoattractive properties, which may support the infiltration
of immune cells into the skin and may boost the local
inflammation (Soruri et al., 2007; Wolf et al., 2008).
Moreover, the directly enhanced induction of chemokines
attracting particularly T helper type 1-cells and dendritic
cells (CCL20) and neutrophilic granulocytes (CXCL1 and
CXCL8) by the cooperative action of IL-19 and IL-17A
might further support this process. Third, IL-19 and IL-17A
synergize with respect to the production of mediators, which
promote the maintenance and effector function of T helper
type 17-cells (IL-1b, IL-23). IL-1b has been reported to be
crucial for the pathogenicity of T helper type 17-cells
(Brereton et al., 2009; Coccia et al., 2012), whereas IL-23
drives their proliferation, survival, and cytokine production
(Ouyang et al., 2008). These IL-19/IL17 effects might be
responsible for the persistence of IL-17-producing cells in
the inflamed skin. Fourth, IL-19 and IL-17A further cooperate
in the induction of IL-20, which contributes to the psoriasis-
typical epidermal alterations.
The results of our study therefore extend the knowledge
about IL-19, a so far largely unexplored mediator. In fact, even
more than 10 years after its discovery by Gallagher´s group
(Gallagher et al., 2000), the actual role of IL-19 remained
obscure. IL-19 expression in vivo has been demonstrated in
inflammation in murine models (Kunz et al., 2006; Wegenka
et al., 2007; Hsing et al., 2008) and human chronic
inflammatory diseases (Kunz et al., 2006; Huang et al.,
2008; Li et al., 2008; Sakurai et al., 2008). Moreover, on the
basis of the association of psoriasis, pustulosis palmoplantaris,
vitiligo, type-I diabetes, ulcerative colitis, and Crohn’s disease
with single nucleotide polymorphisms or the epigenetic
imprint of the IL19, IL20RA, and IL20RB genes, a role of
IL-19 was suggested for these conditions (Koks et al., 2005;
Kingo et al., 2007; Barrett et al., 2009; Kingo et al., 2010;
Yamamoto-Furusho et al., 2011; Nimmo et al., 2012).
However, the so far known effects of IL-19 on primary
human cells are limited and include the prevention of
starvation-induced apoptosis and IL-6 secretion in
rheumatoid arthritis synovial cells, the inhibition of
proliferation, migration, and reactive oxygen species-induced
apoptosis of vascular smooth muscle cells, as well as the
elevation of proliferation of vascular and coronary endothelial
cells (Sakurai et al., 2008; Tian et al., 2008; Gabunia et al.,
2011; Jain et al., 2011; Gabunia et al., 2012). On the other
hand, the gene expression signature of IL-19-treated epidermis
models showed differences from the signature of untreated
controls, as demonstrated by the Ouyang group (Sa et al.,
2007), suggesting clear effects of this cytokine on
keratinocytes. Interestingly, the IL-19 signature also differed
from that of samples treated with its cytokine siblings IL-22 or
IL-24 (Sa et al., 2007).
Our new results regarding the effects of IL-19 on keratino-
cytes very well match both, the excessive IL-19 production in
psoriatic lesions and the absence of skin alterations in IL-19-
transgenic mice reported as ‘‘unpublished observations from
transgenic group of ZymoGenetics’’ by Parrish-Novak et al.
(Parrish-Novak et al., 2002). As described above, a major role
of IL-19 seems to be the amplification of the IL-17A action,
whereas in the absence of IL-17A (like in the IL-19-transgenic
model) no relevant alterations in tissue homeostasis are to be
expected by IL-19.
In addition to the outstanding IL-19 presence in psoriatic
skin, we observed large amounts of this cytokine in the
circulation of patients. Importantly, IL-19 levels highly
exceeded those of known key psoriasis cytokines and rapidly
decreased upon anti-psoriatic therapy. The fact that reduction
of systemic IL-19 levels preceded the clinical improvement
of the patients might be useful for the selection and monitoring
of specific anti-psoriatic therapies, in particular the anti-IL-12/
IL-23 and anti-IL-17 treatment. Wang et al. very recently
demonstrated that the psoriasis-associated Act1D10N
mutation––although accompanied by a high presence of IL-
23, T helper type 17-cells, and IL-17A in the affected skin––
prevented IL-17-related signal transduction and effects (Wang
et al., 2013). Therefore, a selection of psoriasis patients
according to the activity of the IL-23/IL-17 axis by
quantifying systemic IL-19 levels before initiation of such a
therapy might be advisable.
In summary, our findings regarding production, target cells,
and effects of IL-19 present this cytokine as a component of
the IL-23/IL-17 axis, and therefore uncovers a further part of
the pathogenic cascade in psoriasis that can be outlined as
follows: Having infiltrated the skin, lymphoid cells produce IL-
17A and IL-22, both of which drive their individual, and
mediate their cooperative actions. IL-22 on its own inhibits
terminal differentiation, enhances the mobility of keratino-
cytes, and sensitizes these cells to the action of IL-19, IL-20,
and IL-22 by increasing the production of their essential signal
transduction element signal transducer and activator of tran-
scription 3. IL-17A acts as a major inducer of inflammatory
cytokines and chemokines attracting neutrophils, dendritic
cells, and T cells and may support keratinocyte hyperproli-
feration (Nograles et al., 2008; Wolk et al., 2009a; Lai et al.,
2012). IL-17A, TNF-a, and IL-22 synergistically induce the
production of certain anti-bacterial proteins (Liang et al.,
2006; Wolk et al., 2011), of IL-20 (Wolk et al., 2009b), and
of IL-19. IL-20 potentiates the IL-22-initiated inhibition of the
keratinocyte terminal differentiation, whereas IL-19 further
strengthens the immune-stimulatory properties of IL-17A.
Supporting that psoriasis also functions as a model for other
immune-mediated disorders, in which the IL-23/IL-17 axis
often plays a pathogenetic role, we hope that our study will
pave the way for investigating IL-19 functions in further
immune-mediated diseases.
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MATERIALS AND METHODS
Patients
To compare mRNA expressions of different cytokines, punch
biopsies were obtained from diseased skin of 16 adult patients with
chronic plaque psoriasis and from 10 healthy volunteers. To analyze
therapy-induced changes in cutaneous IL-19 expression, biopsies
were obtained from each of 3 patients with chronic plaque psoriasis
before and at defined time points after initiation of UV therapy
(psoralen þ UVA for two patients and narrowband UVB irradiation
for the third patient) or etanercept therapy as indicated, whereas the
same donor lesion per patient was used. To assess IL-19 protein levels
in human skin, biopsies were taken from 5 patients with chronic
plaque psoriasis and from four healthy volunteers.
For assessment of systemic cytokine levels, serum and plasma were
taken from venous blood obtained from 25 patients with chronic
plaque psoriasis, from 13 (Figure 1c) and 26 (Figure 1e) healthy
volunteers, from 17 patients with asthma, from 20 patients with
Crohn’s disease, and from 20 patients who had undergone renal
transplantation (being treated by anti-IL-2R antibody as immunosup-
pressive induction therapy followed by a triple maintenance therapy
with tacrolimus, mycophenolat mofetil, and prednisone). In an
additional approach to analyze therapy-related changes in blood IL-
19 levels, serum was obtained from venous blood of six psoriasis
patients before and 4 weeks after the first application of ustekinumab
and from six patients before and 2–5 weeks after the start of UV-based
combination therapy (two patients with psoralen þ UVA and 4
patients with narrowband UVB irradiation; the UV-accompanying
therapy components included dithranol (all six patients), tar-contain-
ing ointments (all six patients), local corticosteroids (three patients),
calcipotriol (three patients), fumaric acid esters (three patients), and
cyclosporin A (one patient). All skin and blood samples were
approved by the clinical institutional review board of the Charite´
university hospital, Berlin, and written informed consent was
obtained from all participants. The study was conducted according
to the Declaration of Helsinki Principles.
Cell and tissue cultures
Primary human epidermal keratinocytes, dermal fibroblasts, dermal
microvascular endothelial cells, and melanocytes were obtained and
cultured as described previously (Wolk et al., 2009a). For assessment
of IL-19 receptor expression, these cells were directly prepared for
quantitative reverse transcriptase–PCR (qRT-PCR) analysis. To assess
keratinocyte migration, confluent cultures of these cells were starved
for 4 hours by replacing the culture medium with keratinocyte basal
medium gold (Lonza, Verviers, Belgium) without supplements and the
cells were wounded by scratching the surface of the cell monolayers
with a pipette tip (Sarstedt, Nu¨mbrecht, Germany), followed by two
consecutive washes. Thereafter, cells were stimulated with 40 ngml 1
IL-19 (R&D Systems, Wiesbaden-Nordenstadt, Germany) or
10 ng ml 1 EGF (Peprotech, Hamburg, Germany) for 24 hours. Mon-
itoring of scratch wound closure was performed at 0 and 24 hours after
cytokine stimulation by means of AxioVision Release 4.6.3 image
software (Zeiss, Jena, Germany).
To assess cellular proliferation, keratinocytes were either stimulated
or not stimulated (control) with 40 ng ml 1 IL-19, 10 ng ml 1 IL-17A,
or 10 ng ml 1 IFN-b (all from R&D Systems) for 5d in keratinocyte
basal medium gold (Lonza) supplemented according to the manu-
facturer´s instructions, with the exception of EGF.
To investigate IL-19 production and the cooperative action of IL-19
with other cytokines, keratinocytes were stimulated or not stimulated
(control) with IL-19 (100 ng ml 1), 10 ng ml 1 of IL-6, IL-17A, IL-22,
IL-23, TNF-a, GM-CSF, and IFN-g, or combinations of cytokines as
indicated (all from R&D Systems) for 24 hours–48 hours.
EpiDerm-201 underdeveloped human epidermis models were
cultured in inserts at the air–liquid interface as described in
Wolk et al. (2009a) and stimulated by either supplementing the
culture medium or not supplementing (control) with 20 ng ml 1
IL-22, 10 ng ml 1 IL-17A, 10 ng ml 1 IFN-g, 2 ng ml 1 TNF-a,
100 ng ml 1 IL-19, or combinations thereof as indicated (all from
R&D Systems). After 72 hours, biopsies were taken, and the culture
medium was recovered. To quantify IL-19 protein in human skin, skin
biopsies were cultured for 20 hours in keratinocyte medium to allow
IL-19 diffusion into the culture medium.
Mice
Male mice were purchased from Charles River (Wilmington, MA) and
were used at the ages of 96–110d. To study DNFB-induced cutaneous
inflammation, C57BL/6 mice were sensitized with 25ml of 0.5%
(v/v) DNFB in acetone/olive oil (80/20) (Sigma-Aldrich, Taufkirchen,
Germany) and repeatedly challenged on the skin of the ears with
25ml of 0.3% (v/v) DNFB after 5d, 6d, and 7d. One hundred mg of
polyclonal anti-human IL-20R1 goat IgG or the respective isotype
control were given intraperitoneally 1 hours before the first challenge.
Ear thickness was measured before (0 hours) and 24 hours, 48 hours,
and 72 hours after the first challenge. Cytokine levels were analyzed
in ear homogenates 72 hours after the first challenge. To study
lipopolysaccharide-induced systemic inflammation, BALB/c mice
were intraperitoneally injected with 5mg/g mouse lipopolysaccharide
from Escherichia coli 0111:B4 (Sigma-Aldrich). One hundredmg of
polyclonal anti-human IL-20R1 goat IgG or the respective isotype
control (both from R&D Systems) were given 16 hours before the
challenge, and blood plasma was collected 6 hours post lipopoly-
saccharide challenge. All these studies have been approved by the
regional authorities for provisions on labor, health, and technical
safety in Berlin, Germany.
qRT-PCR
Tissue homogenization, isolation of total cellular RNA, reverse
transcription of messenger RNA, and quantitative gene expression
analysis by TaqMan real-time PCR either using the ABI Prism 7700
Sequence Detection System or the Stepone plus (both from Applied
Biosystems, Darmstadt, Germany) from human samples were carried
out as described previously using exon–exon spanning fluorescent
probes (Wolk et al., 2002, 2009b). The expression of human IL-10, IL-
19, IL-20, IL-22, IL-24, IL-26, IL-20R1, IL-20R2, BD2, and BD3 was
detected using of previously established systems (Wolk et al., 2002,
2004, 2011). All other detection systems were purchased from
Applied Biosystems. All expression levels were analyzed in
triplicate and in parallel with those of the housekeeping gene
hypoxanthine phosphoribosyl-transferase 1 to allow calculation
relative to hypoxanthine phosphoribosyl-transferase 1 (Wolk et al.,
2011).
Histology and immunohistochemistry
Frozen EpiDerm-201 tissues were processed as previously described
(Wolk et al., 2009a, 2011). Sections were either stained with a mouse
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antibody to human S100A7 or the corresponding isotype control
antibody or left unstained and were finally counterstained with
Mayer’s hemalaun and covered as described in Wolk et al. (2011).
Living cell layer thickness was measured by means of AxioVision
Release 4.6.3 image software (Zeiss).
ELISA
Quantification of human IL-19, IL-20, IL-22, and CCL20 in
patient samples and/or culture medium was performed using the
respective ELISA kits according to the manufacturer´s instructions
(R&D Systems).
Flow cytometry for cell counting
Cells were stained with propidium iodide staining solution (BD
Biosciences, Heidelberg, Germany), and live cell counts (propidium
iodide-negative) were analyzed by means of a FACS Calibur instru-
ment and Cellquest software (BD Biosciences, Germany). A defined
volume of CaliBRITE FITC-beads (BD Biosciences) added to kerati-
nocyte suspensions served as the internal control.
Statistical analyses
Samples of patients and healthy control participants were compared
using the Mann–Whitney U-test (2-tailed) (*Pp0.05, **Po0.01,
***Po0.001). Significance of differences between treatment groups
of in vitro cultures and of patient samples before, during, and after
therapy was tested by the Wilcoxon matched-pairs signed-rank test
(*Pp0.05, **Po0.01, ***Po0.001). For testing correlations between
parameters, Spearman’s rank correlation test was used (2-tailed)
(*Pp0.05, **Po0.01, ***Po0.001). For all analyses, SPSS 19 soft-
ware (IBM, Ehningen, Germany) was used.
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